Equities analysts expect Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) to report sales of $1.88 million for the current quarter, Zacks reports. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.10 million to $2.33 million. Tetraphase Pharmaceuticals posted sales of $1.49 million during the same quarter last year, which suggests a positive year-over-year growth rate of 26.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $7.32 million for the current fiscal year, with estimates ranging from $5.00 million to $12.31 million. For the next fiscal year, analysts forecast that the company will post sales of $19.39 million per share, with estimates ranging from $8.70 million to $46.03 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. The firm had revenue of $2.53 million for the quarter, compared to analyst estimates of $2.26 million.
Several research firms have recently weighed in on TTPH. HC Wainwright lowered their price objective on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, February 14th. BidaskClub lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. BMO Capital Markets lowered Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective on the stock. in a research note on Wednesday, February 14th. Stifel Nicolaus lowered their price objective on Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, February 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, March 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.22.
Shares of TTPH stock traded down $0.03 during trading hours on Friday, hitting $3.02. The company had a trading volume of 436,527 shares, compared to its average volume of 1,472,187. Tetraphase Pharmaceuticals has a 12 month low of $2.05 and a 12 month high of $8.75. The firm has a market cap of $167.17, a P/E ratio of -1.15 and a beta of 2.61.
In other news, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the sale, the insider now directly owns 8,750 shares in the company, valued at approximately $54,425. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 5.50% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $107,000. Cubist Systematic Strategies LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $195,000. Paloma Partners Management Co acquired a new position in shares of Tetraphase Pharmaceuticals in the 4th quarter worth approximately $210,000. American International Group Inc. boosted its holdings in shares of Tetraphase Pharmaceuticals by 44.1% in the 3rd quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 10,345 shares in the last quarter. Finally, Virtus Fund Advisers LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the 4th quarter worth approximately $376,000. 58.50% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “$1.88 Million in Sales Expected for Tetraphase Pharmaceuticals Inc. (TTPH) This Quarter” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/18/1-88-million-in-sales-expected-for-tetraphase-pharmaceuticals-inc-ttph-this-quarter.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.